 | • レポートコード：MRC2103G125 • 出版社/出版日：Transparency Market Research / 2021年3月10日 • レポート形態：英文、PDF、187ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide Licence | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界の臨床試験市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）分析、研究デザイン別分析、疾患別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・臨床試験の世界市場規模：フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV） ・臨床試験の世界市場規模：研究デザイン別 ・臨床試験の世界市場規模：疾患別 ・臨床試験の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Clinical Trials Market – Scope of the Report
TMR’s report on the global clinical trials market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global clinical trials market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global clinical trials market for the forecast period from 2020–2030.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the clinical trials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global clinical trials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the clinical trials market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the clinical trials market.
The report delves into the competition landscape of the global clinical trials market. Key players operating in the clinical trials market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the clinical trials market profiled in this report.
Key Questions Answered in Clinical trials Market Report
How does the development of clinical trials provide scope of growth in the global clinical trials market?
How alliances and partnerships between players are widening the scope of new line of technologies for clinical trials?
What are the revenue share projections of key segments under various criteria in the clinical trials market during the forecast period?
Which segment is likely to register leading revenue until the end of the forecast period in 2030?
Clinical Trials Market – Research Objectives and Research Approach
The comprehensive report on the global clinical trials market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of procedure for clinical trials.
For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the clinical trials market in terms of phase, study design, indication, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global clinical trials market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Clinical Trials Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Clinical Trials Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Number of Clinical Trials
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry
6. Global Clinical Trials Market Analysis and Forecast, by Phase
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Phase, 2018–2030
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.4. Market Attractiveness Analysis, by Phase
7. Global Clinical Trials Market Analysis and Forecast, by Study Design
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Study Design, 2018–2030
7.3.1. Interventional Trials
7.3.2. Observational Trials
7.3.3. Expanded Access Trials
7.4. Market Attractiveness Analysis, by Study Design
8. Global Clinical Trials Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2018–2030
8.3.1. Autoimmune/Inflammation
8.3.2. Pain Management
8.3.3. Cardiovascular
8.3.4. CNS Condition
8.3.5. Oncology
8.3.6. Diabetes
8.3.7. Obesity
8.3.8. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Clinical Trials Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Clinical Trials Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Phase, 2018–2030
10.2.1. Phase I
10.2.2. Phase II
10.2.3. Phase III
10.2.4. Phase IV
10.3. Market Value Forecast, by Study Design, 2018–2030
10.3.1. Interventional Trials
10.3.2. Observational Trials
10.3.3. Expanded Access Trials
10.4. Market Value Forecast, by Indication, 2018–2030
10.4.1. Autoimmune/Inflammation
10.4.2. Pain Management
10.4.3. Cardiovascular
10.4.4. CNS Condition
10.4.5. Oncology
10.4.6. Diabetes
10.4.7. Obesity
10.4.8. Others
10.5. Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Phase
10.6.2. By Study Design
10.6.3. By Indication
10.6.4. By Country
11. Europe Clinical Trials Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Phase, 2018–2030
11.2.1. Phase I
11.2.2. Phase II
11.2.3. Phase III
11.2.4. Phase IV
11.3.Market Value Forecast, by Study Design, 2018–2030
11.3.1. Interventional Trials
11.3.2. Observational Trials
11.3.3. Expanded Access Trials
11.4.Market Value Forecast, by Indication, 2018–2030
11.4.1. Autoimmune/Inflammation
11.4.2. Pain Management
11.4.3. Cardiovascular
11.4.4. CNS Condition
11.4.5. Oncology
11.4.6. Diabetes
11.4.7. Obesity
11.4.8. Others
11.5.Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness Analysis
11.6.1. By Phase
11.6.2. By Study Design
11.6.3. By Indication
11.6.4. By Country/Sub-region
12. Asia Pacific Clinical Trials Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Phase, 2018–2030
12.2.1. Phase I
12.2.2. Phase II
12.2.3. Phase III
12.2.4. Phase IV
12.3.Market Value Forecast, by Study Design, 2018–2030
12.3.1. Interventional Trials
12.3.2. Observational Trials
12.3.3. Expanded Access Trials
12.4.Market Value Forecast, by Indication, 2018–2030
12.4.1. Autoimmune/Inflammation
12.4.2. Pain Management
12.4.3. Cardiovascular
12.4.4. CNS Condition
12.4.5. Oncology
12.4.6. Diabetes
12.4.7. Obesity
12.4.8. Others
12.5.Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness Analysis
12.6.1. By Phase
12.6.2. By Study Design
12.6.3. By Indication
12.6.4. By Country/Sub-region
13. Latin America Clinical Trials Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Phase, 2018–2030
13.2.1. Phase I
13.2.2. Phase II
13.2.3. Phase III
13.2.4. Phase IV
13.3.Market Value Forecast, by Study Design, 2018–2030
13.3.1. Interventional Trials
13.3.2. Observational Trials
13.3.3. Expanded Access Trials
13.4.Market Value Forecast, by Indication, 2018–2030
13.4.1. Autoimmune/Inflammation
13.4.2. Pain Management
13.4.3. Cardiovascular
13.4.4. CNS Condition
13.4.5. Oncology
13.4.6. Diabetes
13.4.7. Obesity
13.4.8. Others
13.5.Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness Analysis
13.6.1. By Phase
13.6.2. By Study Design
13.6.3. By Indication
13.6.4. By Country/Sub-region
14. Middle East & Africa Clinical Trials Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast, by Phase, 2018–2030
14.2.1. Phase I
14.2.2. Phase II
14.2.3. Phase III
14.2.4. Phase IV
14.3.Market Value Forecast, by Study Design, 2018–2030
14.3.1. Interventional Trials
14.3.2. Observational Trials
14.3.3. Expanded Access Trials
14.4.Market Value Forecast, by Indication, 2018–2030
14.4.1. Autoimmune/Inflammation
14.4.2. Pain Management
14.4.3. Cardiovascular
14.4.4. CNS Condition
14.4.5. Oncology
14.4.6. Diabetes
14.4.7. Obesity
14.4.8. Others
14.5.Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6.Market Attractiveness Analysis
14.6.1. By Phase
14.6.2. By Study Design
14.6.3. By Indication
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2019
15.3. Company Profiles
15.3.1. Laboratory Corporation of America Holdings
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. IQVIA Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Syneos Health
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Parexel International Corporation
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. PPD Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Icon plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Charles River Laboratories, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.8. WuXi AppTec
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Medpace Holdings, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
Table 01: Global Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 02: Global Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030
Table 03: Global Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 04: Global Clinical Trials Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 05: North America Clinical Trials Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 06: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 07: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 08: North America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 09: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 10: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 11: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030
Table 12: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 13: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 15: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030
Table 16: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 17: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 18: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 19: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030
Table 20: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 21: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 22: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030
Table 23: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030
Table 24: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030